Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 2/20 | 0.39 |
| ▸ | KHK | P50053 | 2/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | PLG | P00747 | 3/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | PLAT | P00750 | 4/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL25261129 | 0.99 | SOS1 (0.39) | SOS1KHKGABRA1GABRB2PLG | |
| SCHEMBL30526339 | 0.88 | SOS1 (0.38) | SOS1PLGCHEK1KCNH2 | |
| Hydrochloric Acid SCHEMBL25307453 | 0.86 | SOS1 (0.38) | SOS1PLGCHEK1KCNH2 | |
| SCHEMBL25309589 | 0.86 | PDE1B (0.39) | SOS1CHEK1KCNH2 | |
| SCHEMBL25263324 | 0.79 | SOS1 (0.39) | SOS1KHKGABRA1GABRB2PLG | |
| Hydrochloric Acid SCHEMBL25308694 | 0.78 | SOS1 (0.38) | SOS1KHKGABRA1GABRB2PLG | |
| SCHEMBL25311574 | 0.73 | MAPK1 (0.33) | — | |
| SCHEMBL2525898 | 0.69 | HTR2C (0.42) | KHKGABRA1GABRB2PLGPLAT | |
| SCHEMBL30526338 | 0.68 | SOS1 (0.55) | SOS1 | |
| SCHEMBL25309534 | 0.65 | SOS1 (0.38) | SOS1PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250154147-A1 | NOVEL AMINE-SUBSTITUTED PHTHALAZINES AND DERIVATIVES AS SOS1 INHIBITORS | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE | 2025-05-15 | — | — | US | disclosed |
| EP-4463454-A1 | NOVEL AMINE-SUBSTITUTED PHTHALAZINES AND DERIVATIVES AS SOS1 INHIBITORS | Jazz Pharmaceuticals Ireland Limited (IE) | 2024-11-20 | — | — | EP | disclosed |
| WO-2023135260-A1 | NOVEL AMINE-SUBSTITUTED PHTHALAZINES AND DERIVATIVES AS SOS1 INHIBITORS | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2023-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154147-A1 | NOVEL AMINE-SUBSTITUTED PHTHALAZINES AND DERIVATIVES AS SOS1 INHIBITORS | SOS1, SOS2, SOST | SOS1 1/4885KHK 4794/4885GABRA1 3365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.